期刊
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
卷 37, 期 3, 页码 387-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2011.08.001
关键词
Osteoporosis; Anti-resorptive therapy; Safety concerns
类别
资金
- Agency for Healthcare Research and Quality [T32HS013852, R01HS018517]
- National Institutes of Health [AR053351]
Bisphosphonates reduce the risk of major osteoporotic fractures and are the most commonly used medications for the prevention and treatment of osteoporosis. Although these medications are well tolerated and safe during large-scale clinical trials, several rare and serious adverse events are suspected to be associated with long-term bisphosphonate use. These adverse events include osteonecrosis of the jaw, atypical fractures, and esophageal cancer. This review summarizes studies examining the association between bisphosphonate use and these adverse outcomes, with a focus on large case series and controlled epidemiologic studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据